Our results show that it is feasible to safely induce antibody responses against five ovarian cancer cell surface antigens—Globo-H, GM2, sTn, TF, and Tn—using a unimolecular pentavalent-KLH antigen construct with QS-21 as the immune adjuvant. Here, TF is linked to ovarian carcinoma.